Roivant

Ultragenyx

This biopharmaceutical company develops and commercialises therapies for patients with serious rare and ultra-rare genetic diseases.

Nuvation Bio

This biopharmaceutical company develops and commercialises targeted oncology therapies for patients with cancers that have unmet medical needs.

Krystal Biotech

This biotechnology company develops and commercialises redosable gene therapies for patients with rare genetic diseases, including dystrophic epidermolysis bullosa.

Rocket Pharma

This company develops gene therapies for patients with rare and devastating genetic cardiovascular and haematological diseases.

Recursion Pharma

This company provides a technology platform for drug discovery and development to pharmaceutical partners and develops internal therapeutic candidates for patients with unmet medical needs.

Destiny Pharma

This clinical-stage biotechnology company develops medicines to prevent and treat life-threatening infections for patients in healthcare settings.

XOMA Royalty

This company acquires economic rights to future milestone and royalty payments to provide non-dilutive capital for biotechnology and pharmaceutical developers.

Syndax

This biopharmaceutical company develops and commercialises targeted therapies for adult and paediatric patients with cancer and chronic graft-versus-host disease.